Omnicell (OMCL) Appoint Edward Bousa to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Omnicell Appoints Edward Bousa to Board of Directors
July 12, 2021 8:31 AM EDTMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has increased its number of board seats from 9 to 10, and has appointed Edward P. Bousa to fill the newest seat of the Companys Board of Directors, effective immediately. Mr. Bousa will serve as an independent director and as a member of the Boards Corporate Governance Committee.
Mr. Bousa is a renowned value portfolio manager who brings nearly four decades of experience in institutional asset... More
